Completed PHASE2 INTERVENTIONAL 1-arm NCT01469598

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Phase II Study of Docetaxel and Gemcitabine in Previously Treated Metastatic Esophageal Squamous Cell Cancer

Sponsor: Samsung Medical Center

Conditions Metastatic Carcinoma Recurrent Esophageal Squamous Cell Carcinoma

Updated 6 times since 2017 Last updated: Dec 28, 2015 Started: Aug 31, 2011 Primary completion: Feb 28, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Carcinoma and Recurrent Esophageal Squamous Cell Carcinoma and is currently completed. Samsung Medical Center leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea